Efficacy and tolerability of trabectedin in elderly patients with sarcoma: subgroup analysis from a phase III, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma

BACKGROUND: Treatment options for soft tissue sarcoma (STS) patients aged ≥65 years (elderly) can be limited by concerns regarding the increased risk of toxicity associated with standard systemic therapies. Trabectedin has demonstrated improved disease control in a phase III trial (ET743-SAR-3007) o...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ann Oncol
Main Authors: Jones, R L, Demetri, G D, Schuetze, S M, Milhem, M, Elias, A, Van Tine, B A, Hamm, J, McCarthy, S, Wang, G, Parekh, T, Knoblauch, R, Hensley, M L, Maki, R G, Patel, S, von Mehren, M
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2018
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6454486/
https://ncbi.nlm.nih.gov/pubmed/30084934
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdy253
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados